Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating activities
Net loss	$ (263,063)	$ (260,017)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization	7,216	6,534
Non-cash operating lease cost	3,425	2,176
Non-cash interest expense and amortization of debt issuance costs	1,179	4,892
Payment on notes attributed to accreted interest related to the debt discounts		(22,057)
Acquired in-process research and development		12,271
Loss on write-off of leasehold improvements	386
Stock-based compensation	33,476	39,116
Loss on debt extinguishment, net	40	5,732
Loss (gain) on derivative liabilities	1,300	(4,800)
Loss on marketable and equity investments	15,460	26,958
(Loss) gain on equity method investments	368	59
Write-off obsolete inventory	2,155
Change in fair value of convertible notes	3,748
DIP Facility upfront lender fees and debt issuance costs	4,037
DIP Facility Exit Fee	5,250	0
Increase (decrease) on contingent consideration	3,800	(66,400)
Loss on impairment of intangible assets	12,366	90,780
Deferred income taxes	(353)	(671)
Changes in operating assets and liabilities, excluding effect of acquisitions:
Accounts receivable	(8,256)	(2,389)
Inventory	(1,831)	(11,375)
Accrued payroll	(902)	6,989
Prepaid expenses, deposits and other assets	3,156	4,280
Accounts payable	25,142	1,427
Accrued expenses and other liabilities	35,974	3,976
Deferred revenue	361	(1,587)
Accrued legal settlements	1,797
Income tax payable	12,626
Other	(3,975)	(242)
Net cash used for operating activities	(105,118)	(164,348)
Investing activities
Purchases of property and equipment	(226)	(5,298)
Proceeds received from exit of FortuneBio investment	1,770
Acquisition consideration paid in cash, net of cash acquired		(3,550)
Net cash provided by (used for) investing activities	1,544	(15,392)
Financing activities
Proceeds from DIP Facility, net of lender fees and debt issuance costs	70,963
Proceeds from other short-term debt, net of issuance costs	6,859	57,093
Proceeds from issuance of Scilex shares	16,166
Proceeds from issuance of Scilex convertible debentures	24,000
Proceeds from Scilex eCapital-revolver	17,158
Proceeds from exercises of stock options and warrants	745	805
Repayments of debt and other obligations	(5,285)	(111,339)
Transaction costs related to Business Combination	(1,372)
Payment of dividends	(11)
Net cash provided by financing activities	150,009	215,140
Net change in cash, cash equivalents and restricted cash	46,435	35,400
Net effect of exchange rate changes on cash	(320)	(1,720)
Cash, cash equivalents and restricted cash at beginning of period	23,634	36,665
Cash, cash equivalents and restricted cash at end of period	69,749	70,345
Cash paid during the period for:
Interest	2,228	234
Income taxes	28	(31)
Professional fees paid for reorganization in operating activities	6,604
Supplemental disclosures of non-cash investing and financing activities:
Stock dividends	(14,282)
DIP Facility Exit Fee incurred but not paid	5,250
Virex Health acquisition consideration paid in equity		4,435
Deferred consideration for intangible asset acquisition		3,650
Bridge Loan settlement through ATM proceeds	6,166
Property and equipment costs incurred but not paid	6,388	950
Virex Health, Inc
Investing activities
Acquisition consideration paid in cash, net of cash acquired		(6,544)
Public Offering Of Common Stock And Warrants 2019
Financing activities
Proceeds from equity offerings, net of issuance costs	$ 20,786	$ 268,581